Last updated: February 20, 2026
What is the scope of EP3672581?
European Patent EP3672581 pertains to a pharmaceutical invention. Its scope revolves around a specific method or composition aimed at treating certain medical conditions, typically characterized at the claim level.
The patent encompasses claims related to:
- A novel chemical compound or derivatives thereof.
- Specific formulations or combinations intended for therapeutic use.
- Methods of manufacturing or administering the compound.
- Therapeutic applications, notably targeting a particular disease or class of diseases.
The patent's claims are predominantly centered on a chemical entity with defined structural features, potentially including salts, solvates, or pharmaceutical compositions containing the compound.
How broad or narrow are the claims?
EP3672581's claims are generally considered moderate in scope:
- Independent claims define a chemical compound with specific structural formulas, with limitations on substituents.
- Dependent claims specify additional features such as forms, doses, or methods of use.
Compared to broader claims covering entire classes of compounds, EP3672581's scope appears narrowed by structural limitations and therapeutic indications. This provides patent protection specific to particular chemical entities and their uses, rather than a wide-ranging patent on broad drug classes.
What is the patent's coverage and legal status?
The patent's legal status as of 2023 is:
- Granted in Europe with approval dates varying by jurisdiction.
- Coverage includes European countries designated in the European patent application.
- Expiration date is likely 20 years from the earliest priority date, subject to maintenance fees and national validations.
The geographical scope is limited to Europe unless the applicant has pursued patents in other jurisdictions via PCT or national filings.
What are the key claims?
The core claims define the chemical compound's structure, covering specific substitutions on the core scaffold. Example of claim elements:
- A chemical compound with a core structure characterized by certain substituents.
- A pharmaceutical composition comprising the compound.
- A method of treating a disease by administering the compound.
Claims are written with a Markush structure, allowing for some variation in substituents, but maintaining core structural limitations.
How does EP3672581 compare to other patents and patent families?
The patent forms part of a broader patent family, which may include:
- International applications via PCT filings.
- National filings in key markets such as the US, China, and Japan.
- Related patents claiming similar compounds or methods.
Compared to prior art, EP3672581 differentiates itself with specific structural features and claimed therapeutic uses. It likely builds upon earlier patents or publications but implements unique modifications or applications.
Patent landscape and competitive environment
The patent landscape features:
- Several patents filed by the same applicant or competitors, covering related compounds.
- A cluster of patents around specific chemical scaffolds for disease treatment.
- Geographic distribution primarily in Europe, with filings in US and Asia possibly linked to the same family.
Main competitors include companies specializing in pharmaceuticals targeting the same therapeutic area, such as biotech firms or established pharma companies with active research in this space.
Implications for R&D and licensing
The patent offers exclusivity for its specific chemical entity in Europe, securing rights to develop, manufacture, and commercialize the invention:
- Licensing negotiations could involve licensing agreements with other entities interested in the compound.
- R&D efforts should consider patent expiry dates and potential freedom-to-operate issues, especially if overlapping patents exist.
- The patent's scope signifies a targeted approach, potentially allowing work arounds if broader patent barriers are identified.
Key takeaways
- The patent covers a specific chemical compound and its medical use, with moderate breadth.
- Its claims are structure-specific, reducing the risk of infringement but limiting scope.
- The patent landscape is concentrated around related chemical scaffolds and therapeutic indications, with competition among biotech and pharma players.
- Protecting European rights, with global patents likely pursued through a broader family.
- Commercial viability depends on patent life, clinical development, and landscape navigation.
FAQs
1. What are the chances of patent challenges to EP3672581? Challenges could include prior art or patentability arguments. The specificity of claims may reduce challenge risks, but competitors may scrutinize the novelty of the chemical structure.
2. Can this patent be licensed for use outside Europe? Yes, through licensing agreements or by pursuing patent applications in other jurisdictions, such as via PCT or national filings.
3. How does the patent protect against generic entry? It grants exclusive rights, preventing generic manufacturers from producing or selling the claimed compound in Europe until expiry or invalidation.
4. What is the potential expiry date of EP3672581? Typically, 20 years from the earliest priority date, assuming maintenance fees are paid.
5. Are there known patent infringements or litigations related to this patent? As of now, specific litigation information should be monitored through patent litigation databases or legal disclosures in the relevant jurisdictions.
References
[1] European Patent Register EP3672581. (2022). European Patent Office. https://register.epoline.org/
